Sulis Therapeutics

Sulis Therapeutics is a Danish biotechnology company focused on developing targeted protein degradation therapies for autoimmune, inflammatory, and chronic fibroinflammatory diseases. Founded in 2024 as a spinout from Aarhus University, the company leverages its proprietary targeted protein degradation technology to selectively deplete Stimulator of Interferon Genes (STING). Its lead preclinical candidate, SP2H, is a selective STING degrader designed to remove STING-associated inflammatory changes while preserving normal immune function. Sulis Therapeutics is advancing its pipeline for indications such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and STING-associated vasculopathy with onset in infancy (SAVI).